BidaskClub downgraded shares of AVEO Pharmaceuticals (NASDAQ:AVEO) from a sell rating to a strong sell rating in a research note issued to investors on Tuesday.
AVEO has been the subject of a number of other reports. Zacks Investment Research lowered AVEO Pharmaceuticals from a hold rating to a sell rating in a research note on Wednesday, December 6th. Seaport Global Securities reissued a buy rating on shares of AVEO Pharmaceuticals in a research note on Friday, October 6th. B. Riley assumed coverage on AVEO Pharmaceuticals in a research note on Monday, November 13th. They set a buy rating and a $5.00 price target for the company. Finally, assumed coverage on AVEO Pharmaceuticals in a research note on Wednesday, November 15th. They set a buy rating and a $5.00 price target for the company. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company’s stock. The company currently has a consensus rating of Hold and a consensus target price of $4.05.
AVEO Pharmaceuticals (NASDAQ:AVEO) opened at $3.10 on Tuesday. AVEO Pharmaceuticals has a one year low of $0.50 and a one year high of $4.24. The company has a debt-to-equity ratio of -0.32, a current ratio of 2.33 and a quick ratio of 2.33.
COPYRIGHT VIOLATION NOTICE: “BidaskClub Downgrades AVEO Pharmaceuticals (AVEO) to Strong Sell” was originally published by Community Financial News and is owned by of Community Financial News. If you are reading this article on another site, it was copied illegally and republished in violation of US and international copyright & trademark laws. The correct version of this article can be read at https://www.com-unik.info/2018/01/13/bidaskclub-downgrades-aveo-pharmaceuticals-aveo-to-strong-sell.html.
About AVEO Pharmaceuticals
AVEO Pharmaceuticals, Inc is a biopharmaceutical company. The Company’s platform delivers insights into cancer and related disease. The Company’s product candidates include Tivozanib, Ficlatuzumab, AV-203 and AV-380. Tivozanib is a selective long half-life vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI) that inhibits over three VEGF receptors.
Receive News & Ratings for AVEO Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVEO Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.